VolitionRx Ltd. - VNRX Net earnings per share (EPS TTM)

VolitionRx Limited (VNRX) is a reputable player in the field of epigenetics, whose Nu.Q platform is valued by laboratories for its precision and ease of implementation. The creation of affordable nucleosome-based assays provides the company with significant pricing power in human and animal diagnostics. The current EPS stands at 33.50, and this chart illustrating the historical price action of this metric is available on the GURU.Markets platform.
VolitionRx Ltd. - analytical breakdowns and key metrics (VNRX)

To minimize risk, investors must filter out issuers with negative profit trends. The relative EPS YoY TTM growth analysis on GURU.Markets measures the rate of change in net income per share relative to the sector average, revealing the impact of operating expenses on profitability. For VolitionRx Limited (VNRX), this metric is critical, as the development stage of epigenetic tests has not yet generated a stable cash flow.